Background. Invasive aspergillosis (IA) is a life-threatening infection for immunocompromised patients. Improvement in IA outcome has been hampered by lack of early prognostic factors, namely, those available before starting chemotherapy (baseline) or early in the course of IA (nonbaseline). We hypothesized that prognostic factors can be identified before chemotherapy, ≤7 days from the first positive serum Aspergillus galactomannan index (s-GMI).
Invasive aspergillosis (IA) is the leading invasive mycosis in patients with hematological malignancies and remains associated with unfavorable outcomes [1] . Various prognostic factors have been identified, including extent of the infection, persistent neutropenia, and use of systemic corticosteroids [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . However, most of these variables are available only after the diagnosis of IA and cannot be successfully applied toward early intervention or treatment modification [18] .
Identification of prognostic factors that are available before starting chemotherapy or early during the disease course would improve our ability to individualize antifungal strategies [18] and to design clinical trials of IA, a challenging task when applying conventional criteria, particularly when Aspergillus-specific laboratory markers are not included in the primary study end point [18] . Indeed, a recently completed large randomized clinical trial enrolled 454 patients at 165 multinational sites over approximately 3 years but failed to meet the primary end point for superiority of combination therapy over monotherapy [19] . This likely occurred because the study's primary end point, 6-week all-cause mortality, was not Aspergillus-specific and mortality can be caused by several non-IA related factors, such as graft-versus-host disease and others [18] .
Galactomannan is a cell wall component of Aspergillus species that is released by growing hyphae during active aspergillosis. The serum Aspergillus galactomannan index (s-GMI) is an excellent surrogate marker for the diagnosis of IA in patients with hematological cancers [18] , and s-GMI positivity precedes the overt manifestations of IA [20] . Furthermore, we and others have shown that s-GMI serves as a valid surrogate end point for clinical outcome, with a strong correlation between normalization of s-GMI and treatment success and survival [21] [22] [23] [24] [25] . We therefore hypothesized that simple and objective early prognostic factors for IA can be identified before commencing the chemotherapy course that precedes IA development and can be detected early during the disease course by using s-GMI, an Aspergillus-specific marker.
PATIENTS AND METHODS
We conducted a retrospective study of all episodes of IA in patients with multiple myeloma cared for at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, between January 2003 and December 2009. The study was approved by the Institutional Review Board. Evaluation included a review of medical records and radiologic tests, including computerized axial tomography of sinuses and lungs.
One hundred and sixteen episodes of IA were diagnosed during the study period, as previously reported [26] . For this analysis, we focused on patients who developed IA during neutropenia. Ninety-eight episodes were evaluable after exclusion of 12 that developed in nonneutropenic settings, 4 that were recurrent, and 2 during which s-GMI was negative. Patients were managed according to predefined standards of care, as described elsewhere [26] , including use of fluconazole prophylaxis and serial measurement of s-GMI (≥3 times/week) during periods at risk (ie, following myelosuppressive chemotherapy or receipt of a melphalan-based conditioning regimen for autologous hematopoietic stem cell transplantation [MEL-ASCT]). Mould-active agents (voriconazole or liposomal amphotericin B) were used at the first positive s-GMI and confirmation of IA on the basis of host, clinical, and radiologic criteria. Cases were classified as proven or probable, according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [27] , or as probable, without prespecified radiologic findings [26] .
Three response criteria were used to examine prognostic factors: response according to s-GMI kinetics, with survival, as previously defined [21] ; the EORTC/MSG response definitions [28] ; and 6-week survival regardless of cause of death. Response by s-GMI kinetics was defined as survival and repeatedly negative s-GMI for ≥2 weeks after the first negative s-GMI in the absence of new extrapulmonary lesions of IA, while failure was defined as persistently positive s-GMI. Death within the 14-day period of negative s-GMI was also considered failure, unless aspergillosis could not be documented at autopsy.
We examined potential predictors immediately prior to starting the chemotherapy regimen after which IA was diagnosed (baseline) and potential predictors after IA was diagnosed (nonbaseline). Baseline variables included sex, age, body surface area (BSA), body mass index (BMI; defined as the weight in kilograms divided by the square of the height in meters), myeloma status, treatment (chemotherapy or MEL-ASCT), number of prior ASCTs, cumulative corticosteroid doses ( prednisone equivalent) and receipt of other immunosuppressants (60 days and 30 days before diagnosis of IA, respectively), white blood cell (WBC) count, absolute neutrophil count (ANC), absolute lymphocyte count, platelet count, absolute CD4 cell count, creatinine clearance rate, serum bilirubin level, cytomegalovirus (CMV) serologic status, and iron overload, defined as increased marrow iron stores [29] .
Nonbaseline variables included ANC at diagnosis of IA; CMV reactivation, defined as ≥600 copies/mL by plasma quantitative polymerase chain reaction; site of IA (lung, sinuses, other); value of first positive s-GMI; normalization of s-GMI ≤7 days from the first positive s-GMI; duration of neutropenia (ANC, <500 neutrophils/mm 3 ); neutrophil recovery (ANC, ≥500 neutrophils/mm 3 on 3 consecutive days);
and cumulative corticosteroid doses given ≤6 weeks after diagnosis. Separate statistical analyses for baseline and nonbaseline variables were conducted. Univariate analysis was performed using the Fisher or χ 2 test (as appropriate) for categorical variables and the Wilcoxon test for continuous variables. Variables with a P value <.1 were entered in a multivariate logistic regression analysis. Receiver operating characteristic (ROC) curves were used to determine the best cutoff for the continuous variables that were significant by multivariate analysis. Kaplan-Meyer curves were constructed and compared using the log-rank test. All tests were 2-tailed, and P values <.05 were considered statistically significant.
RESULTS
The characteristics of 98 evaluable cases of IA are shown in , with a sensitivity of 62% and a specificity of 72%. A Kaplan-Meier curve ( Figure 1 ) shows a 91% probability of response at 6 weeks for patients with a baseline platelet count ≥65,000 platelets/mm 3 , compared with only 68% for patients with a lower count (P = .01).
Normalization of s-GMI within 7 days and neutrophil recovery were the only 2 nonbaseline variables that predicted good outcome by univariate analysis ( (Table 3) .
Factors Associated With Response, as Defined by EORTC/MSG Criteria
Response was observed in 59 of 93 cases (63.4%). Assessment was not possible in 5 patients (lost to follow-up before the 6-week time point). Baseline variables associated with response by univariate analysis were higher BMI, platelet count, and creatinine clearance rate; lower serum bilirubin level; and controlled myeloma (Table 2 ). Higher baseline platelet count (OR, 1.009; 95% CI, 1.002-1.017; P = .01) and higher baseline creatinine clearance rate (OR, 1.024; 95% CI, 1.006-1.042; P = .009) were independent predictors by multivariate analysis ( Table 3 ). The cutoffs for platelet count and creatinine clearance rate were 65,000 platelets/mm 3 (sensitivity 66%, specificity 71%) and 53 mL/min (sensitivity 76%, specificity 53%), respectively. The probability of response was 83% when both variables were above cutoffs, 69% when platelet levels were ≥65,000 platelets/mm 3 but the creatinine clearance rate was <53 mL/ min, and 61% when the creatinine clearance rate was ≥53 mL/ min but platelet levels were <65,000 platelets/mm 3 . When both variables were below cutoffs, the probability of response was only 28% (P < .001) ( Figure 2 ).
Higher ANC at diagnosis of IA, neutrophil recovery, and normalization of s-GMI within 7 days were the only nonbaseline variables significantly associated with response by univariate analysis (Table 2) , while only normalization of s-GMI within 7 days (OR, 2.900; 95% CI, 1.009-8.333; P = .048) remained significant by multivariate analysis (Table 3) .
Factors Associated With 6-Week Survival
Sixty-seven patients (68.4%) were alive at 6 weeks. Baseline predictors of survival by univariate analysis included higher BMI, WBC, platelet counts, and creatinine clearance rate; lower serum bilirubin level; lower number of prior ASCTs; nonreceipt of immunosuppressants other than corticosteroids; and controlled myeloma ( Table 2 ). Only higher creatinine clearance rate (OR, 1.031; 95% CI, 1.010-1.052; P = .003) remained significant on multivariate analysis with a cutoff of 53 mL/min (sensitivity 78%, specificity 58%) ( Table 3) .
Higher ANC at diagnosis of IA, s-GMI normalization within 7 days, and neutrophil recovery were associated with 6-week survival by univariate analysis (Table 2) but not by multivariate analysis (Table 3 ). Figure 3 shows the KaplanMeier survival curves according to normalization of s-GMI ≤7 days after the first positive s-GMI and neutrophil recovery.
DISCUSSION
To our knowledge, our study is the first to examine the significance of baseline prechemotherapy prognostic factors for neutropenia-related aspergillosis and to do so using platelet count and renal function, 2 simple, inexpensive to measure, widely available, and routinely collected data. Two nonbaseline variables, normalization of s-GMI ≤7 days after the first positive s-GMI and neutrophil recovery, were also identified as independent prognostic factors for IA.
That platelet count independently predicted the outcome of IA should not be surprising. Indeed, platelet counts are good indicators of bone marrow reserve and hence the likelihood of timely neutrophil recovery; platelet counts independently predict the ability to mobilize autologous peripheral blood stem cells [30] and hematological recovery following highdose chemotherapy and ASCT [31] and are used to plan dosage schedules for antineoplastic therapies [32, 33] . The protective effect of higher platelet counts may also result from the ability of platelets to interfere with the virulence of Aspergillus species [34] and to act synergistically with antifungal agents against these pathogens [35] .
Several chemotherapeutic agents, including intravenous MEL used in MEL-ASCT, are renally excreted, and MEL-treated patients with renal failure have higher risk for severe oral mucositis as a result of higher drug exposure [36] . Higher MEL exposure is also known to result in more severe and prolonged myelosuppression and immunosuppression [37] . Our finding that patients with renal dysfunction experienced worse outcomes is in keeping with these reports [36, 37] and with our prior analysis identifying elevated serum creatinine level as an independent risk factor for severe oral mucositis following MEL-ASCT [38] . The importance of creatinine clearance rate as a prognostic factor for IA in settings other than multiple myeloma deserves further investigation. Fifteen studies examined the prognostic factors for IA among patients with hematologic cancers (Table 4) . Unfortunately, most variables evaluated were not obtained at baseline and hence cannot be applied towards early intervention, therapy modification, or stratification in clinical trials [18] .
To better appreciate the reported prognostic factors for IA, we classified them as baseline ( prechemotherapy) and nonbaseline factors, the latter further classified as nonbaseline, pre-IA (ie, after chemotherapy but before IA diagnosis) and nonbaseline, post-IA (after IA diagnosis).
Two studies of patients with acute leukemia treated with nonmyeloablative chemotherapy identified nonremission status as the only predictor of poor outcome [2, 14] , while 3 of 5 studies of allogeneic SCT [3, 6, 7, 12, 17] identified pulmonary dysfunction, HLA-mismatched transplantation and nonmyeloablative conditioning [7] , conditioning without antithymocyte globulin [17] , and, surprisingly, younger age [6] . Five of 8 studies that evaluated patients with different underlying diseases and therapies, including SCT [4, 5, [8] [9] [10] [11] 16] , did not identify baseline prognostic factors, while 3 suggested that relapsed malignancy [4] , prior noninfectious respiratory disease [9] , and receipt of 0.3 mg/kg/day of prednisone for >3 weeks ≤90 days before IA [22] negatively affected outcome. The large variation in early outcome predictors among these studies is likely the result of large heterogeneity in underlying diseases, therapeutic modalities, diagnostic methods, and antifungal strategies [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Nonbaseline pre-IA prognostic factors were identified in 4 of 15 studies, including neutropenia ≤30 or ≤60 days before IA [8, 12] , serum bilirubin level of >6.5 mg/dL and serum creatinine level of >2.5 mg/dL [7] , and prednisone dose of ≥7 mg/kg ≤1 week before IA diagnosis [3] . However, the common occurrence of these events and their timing in relation to IA limit their clinical usefulness.
Several post-IA factors were associated with poor outcomes, including extensive pulmonary or disseminated IA [4, 6, 7, [9] [10] [11] , corticosteroids [6, 7, 9, 10, 12, 17] , neutropenia (at diagnosis of IA or duration of persistent neutropenia) [5, 7, 11, 16] , thrombocytopenia [17] , renal [9, 12, 17] and other organ dysfunction [10, 12, 16] , and relapsed malignancy [4, 9] . Severe graft-versushost disease negatively impacted outcome in one study [3] . Unfortunately, these post-IA variables have limited clinical application because they are considered "too little, too late" [18] .
Only 3 studies evaluated the prognostic significance of s-GMI. Positive s-GMI at diagnosis did not impact outcome in one study [8] but was associated with lower 12-week survival by univariate but not multivariate analysis in another [9] , while higher s-GMI at diagnosis of IA independently predicted poor 6-and 12-week survival in a third, in which the rate of s-GMI decay ≤7 days after the first positive s-GMI was significantly associated with outcome [22] . Although we could not confirm a prognostic significance of a high s-GMI at diagnosis, the superior outcomes we observed among our patients whose s-GMI normalized ≤7 days are in agreement with this report [22] and with others showing strong correlation between declining s-GMI values and positive outcomes [21] [22] [23] [24] [25] .
Our results have important clinical and research implications. Stratification of patients into low-, intermediate-, or high-risk categories according to baseline platelet count and creatinine clearance rate may allow risk-adapted strategies to IA [18] with low risk are patients best managed with diagnostic-driven, preemptive s-GMI-guided therapy while mouldactive prophylaxis is reserved for patients at high risk of failure to pre-emptive therapy. Managing patients at intermediate risk can be individualized depending on the rapid availability of s-GMI results and other local considerations.
We previously reported that response based on s-GMI kinetics correlated well with the EORTC/MSG response criteria but were more objective and allowed earlier response classification (3 weeks) than the EORTC/MSG 6-week time point [21] . We now show that clinicians can use s-GMI to assess response at an even earlier time point, ≤7 days after the first positive s-GMI.
Because most patients with myeloma receive high doses of corticosteroids, usually in fixed predefined doses, and because of the narrow age distribution of this population [39] , we could have missed a potential association between outcomes and older age or cumulative corticosteroid doses [3, 7, 12, 22] . Our focus on a homogeneous population (same underlying disease, care at a single institution with standardized antineoplastic therapies, and infectious disease management) represents an important strength because it eliminates the confounding variables associated with heterogeneous populations with different diseases and therapies. Nonetheless, the role of baseline platelet count and creatinine clearance rate as prognostic factors should be confirmed in other patient populations.
We conclude that platelet count and renal function, 2 simple, inexpensive to measure, widely available, and routinely collected laboratory data, can predict the outcome of neutropenia-related IA, even before the start of chemotherapy, and that the evaluation of s-GMI ≤7 days after the first positive s-GMI provides clinicians with the opportunity to modify therapy early during the course of IA. 
Notes

